某院抗肿瘤中成药临床应用调查与分析

Clinical Application of Anti-Tumor Chinese Patent Medicines in a Hospital

目的促进临床安全、合理使用抗肿瘤中成药。方法选取医院2017年7月至2018年3月肿瘤科、血液科及放疗科的患者病历,对抗肿瘤中成药的使用情况进行统计与分析。结果使用抗肿瘤中成药的病例数为239例(50.85%);抗肿瘤辅助中成药在抽取病例中占比为39.15%(184/470),在全院中成药使用占比为38.62%(258/668);使用抗肿瘤治疗及辅助中成药病例数分别为113例(24.04%)、134例(20.06%);抗肿瘤治疗及辅助中成药单用率分别为84.96%和70.65%;抗肿瘤治疗中成药临床使用率居前3位的是艾迪注射液、华蟾素胶囊(片)、康艾注射液;抗肿瘤辅助中成药临床使用率居前3位的是香菇多糖注射液、地榆升白片、参麦注射液;发生率排名居前3的、使用不合理情况为用法、用量不适宜,溶剂不适宜,联合用药不适宜或不良相互作用;艾迪注射液、香菇多糖注射液的不合理使用率分别为32.20%和16.41%。结论抗肿瘤中成药在医院使用情况尚可,但仍需重视临床用药安全性、合理性。

Objective To promote safe and rational use of anti-tumor Chinese patent medicines in the clinic.Methods The medical records of patients in the Departments of Oncology,Hematology and Radiotherapy from July 2017 to March 2018 were selected to analyze the use of anti-tumor Chinese patent medicines.Results Totally 239 cases(50.85%) used anti-tumor Chinese patent medicines.The proportion of anti-tumor adjuvant Chinese patent medicines was 39.15%(184/470) in the selected cases and 38.62%(258/668) in all the cases used Chinese patent medicines in our hospital.Totally 113 cases(24.04%) were treated with anti-tumor therapy and 134 cases(20.06%) were treated with adjuvant Chinese patent medicines.The single-use rates of anti-tumor therapy and adjuvant Chinese patent medicines were 84.96% and 70.65%,respectively.Aidi Injection,Huachansu Capsules(Tablets) and Kang'ai Injection ranked the top three in the clinical use rates of Chinese patent medicines in anti-tumor therapy.Lentinan Injection,Diyushengbai Tablets and Shenmai Injection ranked the top three in the clinical use rates of anti-tumor adjuvant Chinese patent medicines.Inappropriate usage and dosage,inappropriate solvent and inappropriate combination of drugs or adverse interactions ranked the top three in the irrational use of antitumor Chinese patent medicines.The irrational use rates of Aidi Injection and Lentinan Injection were 32.20% and 16.41%,respectively.Conclusion The application of anti-tumor Chinese patent medicines in our hospital is feasible,but attention should be paid to the safety and rationality of clinical medication.